Filing Details

Accession Number:
0001181431-13-046845
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-08-28 20:01:15
Reporting Period:
2013-08-26
Filing Date:
2013-08-28
Accepted Time:
2013-08-28 20:01:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1001233 Sangamo Biosciences Inc SGMO Biological Products, (No Disgnostic Substances) (2836) 680359556
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1202278 G Dale Ando C/O Sangamo Biosciences Inc.
Point Richmond Tech Cntr, 501 Canal Blvd
Richmond CA 94804
Vp, Therapeutic Dev. & Cmo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-08-26 10,000 $3.61 96,798 No 4 M Direct
Common Stock Acquisiton 2013-08-26 1,000 $3.45 97,798 No 4 M Direct
Common Stock Disposition 2013-08-26 11,000 $10.04 86,798 No 4 S Direct
Common Stock Acquisiton 2013-08-26 2,000 $5.19 88,798 No 4 M Direct
Common Stock Disposition 2013-08-26 2,000 $10.04 86,798 No 4 S Direct
Common Stock Disposition 2013-08-26 2,000 $10.04 84,798 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2013-08-26 10,000 $0.00 10,000 $3.61
Common Stock Employee Stock Option (Right to Buy) Disposition 2013-08-26 1,000 $0.00 1,000 $3.45
Common Stock Employee Stock Option (Right to Buy) Disposition 2013-08-26 2,000 $0.00 2,000 $5.19
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
30,000 2014-08-01 No 4 M Direct
198,000 2018-12-09 No 4 M Direct
21,000 2014-12-19 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 25, 2013.
  2. Includes 50,000 shares and 35,000 shares subject to restricted stock units granted on December 8, 2011 and December 6, 2012, respectively, which will be issued as such units vest in accordance with their terms.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.99 to $10.13,inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.99 to $10.135,inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.99 to $10.135,inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  6. All shares underlying this option are vested and immediately exercisable.